Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Lisa Maree Williams/Getty Images

AstraZeneca's COVID-19 vaccine trial has been put on pause after researchers suspected an adverse reaction in a participant in the United Kingdom, a spokesperson for the company told Stat News.

Why it matters: There are presently nine vaccine candidates in Phase 3 trials. AstraZeneca’s is one of the most promising candidates, and is the first known Phase 3 vaccine trial to be halted.

Of note: It is unclear what the unfavorable reaction was and when it occurred, but the participant is expected to recover. It's also not known who paused the study, how severe or rare the reaction may be and how long the hiatus could last.

  • A variety of responses may be flagged for possible adverse reactions, including hospitalization, life-threatening illness and death.

What they're saying: The halt is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials," AstraZeneca said in a statement per Stat News.

"In large trials illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline."

The big picture: AstraZeneca started its Phase 3 trial in the U.S. in late August. The process is taking place across 62 sites throughout the country.

  • Phase 2 and 3 trials previously began in the U.K., Brazil and South Africa.

Go deeper

Scoop: Vice President Pence to receive televised vaccine shot

Vice President Mike Pence. Photo: SOPA Images / Getty Images

Vice President Mike Pence plans to receive his coronavirus vaccine shot on camera Friday morning at the White House to build "vaccine confidence" among the American people, according to an administration official with direct knowledge of the plans.

Driving the news: Details are still being worked out, but Pence wants the TV networks to carry the moment live in the morning, the source said, to maximize the audience for the vaccination.

Dec 17, 2020 - Health

Extra doses of Pfizer vaccine could expand U.S. supply

An infectious disease doctor in California receives the Pfizer vaccine on Thursday, Dec. 17. Photo: Keith Birmingham/MediaNews Group/Pasadena Star-News via Getty

Pfizer vaccine vials contain extra doses that could boost America's supply by up to 40%, the Food and Drug Administration announced on Wednesday.

Driving the news: The U.S. has 100 million doses of the Pfizer-BioNTech vaccine to inoculate 50 million people but declined to buy more doses earlier this year. The vaccine is first being administrated to frontline health care workers and nursing home residents and staff.

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Health: The end of quarantine — CDC updates guidance on airborne COVID-19.
  2. Politics: Oklahoma secures $2.6 million refund for hydroxychloroquine purchase — Why Biden's latest vaccine goal is his hardest yet.
  3. Vaccines: Pfizer begins application for full FDA approval of COVID-19 vaccine — Moderna says its COVID booster shot shows promise against variants.
  4. Economy: U.S. adds just 266,000 jobs in April, far below expectations.
  5. World: Asia faces massive new COVID surgeIndia records its deadliest day of the pandemic.
  6. Variant tracker: Where different strains are spreading.